{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:53:22Z","timestamp":1792720402384,"version":"4.5.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>An association between certain immunomodulatory therapies (rituximab, ipilimumab, and other immune checkpoint inhibitors) and inflammatory (non-ischemic and non-infectious) colitis in oncologic and non-oncologic patient populations is well documented in the medical literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this case series is to describe adverse event reports of new onset, inflammatory colitis in association with ocrelizumab in patients with multiple sclerosis submitted to U.S. Food and Drug Administration (FDA) or published in the medical literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The FDA Adverse Event Reporting System (FAERS) and medical literature were searched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A review of postmarketing cases from FAERS and published medical literature identified 38 cases consistent with inflammatory, non-ischemic, and non-infectious colitis in association with ocrelizumab. The median time-to-onset was 8\u2009months. Cases were reported using the following diagnostic terms: Crohn\u2019s disease (13), unspecified colitis (11), microscopic colitis (5), ulcerative colitis (5), medication-induced colitis (3), and autoimmune colitis (2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This case series highlights ocrelizumab induced immune-mediated colitis that can be clinically severe and potentially life-threatening. Based on the findings of this review, the ocrelizumab Prescribing Information was amended to include immune-mediated colitis in the Warnings and Precautions section.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585231195854","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:03:02Z","timestamp":1694692982000},"page":"1275-1281","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Immune-mediated colitis associated with ocrelizumab: A new safety risk"],"prefix":"10.1177","volume":"29","author":[{"given":"Tiffany","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Brinker","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Croteau","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Neurology II, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1795-1542","authenticated-orcid":false,"given":"Laura E","family":"Baldassari","sequence":"additional","affiliation":[{"name":"Division of Neurology II, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Stevens","sequence":"additional","affiliation":[{"name":"Division of Neurology II, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Neurology II, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli","family":"Tomaino","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Office of Neurology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"deFonseka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Office of Neurology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Altepeter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Office of Neurology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy M","family":"Kortepeter","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"bibr1-13524585231195854","unstructured":"Ocrevus [package insert]. South San Francisco, CA: Genentech, 2022, https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9da42362-3bb5-4b83-b4bb-b59fd4e55f0d"},{"key":"bibr2-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00843-8"},{"key":"bibr3-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00704-w"},{"issue":"1","key":"bibr4-13524585231195854","first-page":"58","volume":"12","author":"Lipka S","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"bibr5-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000553"},{"key":"bibr6-13524585231195854","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5119-20"},{"key":"bibr7-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12744"},{"key":"bibr8-13524585231195854","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s adverse event reporting system (FAERS), https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ (2018, accessed 1 July 2020)."},{"key":"bibr9-13524585231195854","unstructured":"Postmarketing reporting of adverse drug experiences. Electronic code of federal regulations title 21: Food and drugs part 314, https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?SID=eb822077c27330d63a938f32733fd508&mc=true&node=se21.5.314_180&rgn=div8. (accessed 1 July 2020)."},{"key":"bibr10-13524585231195854","unstructured":"US Food and Drug Administration. Guidance for industry: Good pharmacovigilance practices and pharmacoepidemiologic assessment, 2005, https:\/\/www.fda.gov\/files\/drugs\/published\/Good-Pharmacovigilance-Practices-and-Pharmacoepidemiologic-Assessment-March-2005.pdf"},{"key":"bibr11-13524585231195854","unstructured":"US Food and Drug Administration. Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff, 2019, https:\/\/www.fda.gov\/media\/130216\/download?attachment"},{"key":"bibr12-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa057"},{"key":"bibr13-13524585231195854","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000709112.86831.18"},{"key":"bibr14-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/zaa010.001"},{"key":"bibr15-13524585231195854","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i8.2569"},{"issue":"3","key":"bibr16-13524585231195854","first-page":"447","volume":"34","author":"Barnes A","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"bibr17-13524585231195854","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000742"},{"key":"bibr18-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.058560"},{"key":"bibr19-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00274-1"},{"key":"bibr20-13524585231195854","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795"},{"key":"bibr21-13524585231195854","first-page":"8858378","volume":"2020","author":"Lee HH","year":"2020","journal-title":"Case Rep Gastrointest Med"},{"key":"bibr22-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2015-0110"},{"key":"bibr23-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8340-8"},{"key":"bibr24-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04866.x"},{"key":"bibr25-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3682"},{"key":"bibr26-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61649-8"},{"issue":"3","key":"bibr27-13524585231195854","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000214","volume":"3","author":"Lambert-Jenkins K","year":"2022","journal-title":"JPGN Rep"},{"key":"bibr28-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211035542"},{"key":"bibr29-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.225482"},{"key":"bibr30-13524585231195854","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1854847"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231195854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585231195854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231195854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:12:43Z","timestamp":1777695163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585231195854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/13524585231195854"],"URL":"https:\/\/doi.org\/10.1177\/13524585231195854","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}